DCTH - Delcath Stock Price

Delcath Systems, Inc. (DCTH) is moving toward mass sales following the certification of the HEPZATO KIT for the treatment of liver metastases. This daily price chart below illustrates the quotes, where the current figure stands at 20.07. The business relies on partnerships with clinics and the acquisition of patents. Demand for these services remains stable, while financial success is tied to technology implementation and test results.

Delcath Corp - DCTH Price (period 07/04/2022 - 11/11/2026)

Metric breakdowns and analytics for Delcath Systems Inc (DCTH)

- stock quotes and analyst forecast:

Stock Price Delcath Systems, Inc.|DCTH - Broker Consensus Forecast

- market capitalization statistics:

Market Capitalization Delcath Systems Inc|DCTH - Real Price to Acquire Entire Company

- book capitalization information:

Accounting Value per Share Delcath Systems|DCTH - Total Net Assets|Market Capitalization to Book Value Ratio delcath.com|DCTH - Aggregate Asset Value

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

DCTH - Company Net Income|Expected Profit Delcath Systems, Inc.|DCTH - Company Value to Net Income|Projected Price to Earnings Delcath Systems|DCTH - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Delcath Systems Inc|DCTH - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Delcath Systems|DCTH - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months delcath.com|DCTH - Earnings per share increase in current year|Earnings growth forecast for next year Delcath Systems, Inc.

Comprehensive company analysis:DCTH Delcath Systems, Inc.

Delcath Systems, Inc. (DCTH) is developing a unique isolated hepatic perfusion chemotherapy technology that minimizes systemic toxicity in oncology treatment. The current share price of 20.07 represents the market consensus on the capitalization of this medical solution, where every point in the price chronology records the final value of the business stake, allowing investors to assess the balance between hype-driven demand and the risk of correction.

Who Delcath Systems, Inc. competes with